J Cannabis Res. 2025 Jul 12;7(1):43. doi: 10.1186/s42238-025-00307-6.
ABSTRACT
INTRODUCTION: The use of medicinal cannabis is increasing worldwide and has applications in managing a wide range of conditions, including neurological, rheumatological, and gastrointestinal diseases. Despite its growing prevalence, there are limited data on patterns of cannabis prescription across varying disease groups and demographic subgroups.
METHODS: This retrospective observational cohort study analysed cannabis usage patterns among 263 patients from the cannabis user clinic at Rabin Medical center (RMC), a tertiary hospital in Israel. To minimise the inclusion of recreational cannabis users, only patients aged 30 years and older were included. Patients were categorised into three groups based on their primary medical condition: neurological (n = 63), rheumatological (n = 106), and gastrointestinal (n = 94). Data collected included: demographic information, cannabis dosage, Tetrahydrocannabinol (THC) content, cultivated variety preference (sativa vs. Indica), and method of consumption (smoking vs. oil). Statistical analyses were conducted using ANOVA, Kruskal-Wallis, chi-square, and t-tests to compare cannabis prescription patterns between disease and demographic groups.
RESULTS: Significant differences in cannabis prescription patterns were observed across disease groups. Patients with gastrointestinal conditions were prescribed the highest mean monthly cannabis dose (22.26 ± 13.60 g), while those with neurological conditions had the highest oil consumption (31.75%). Sex-based differences were notable, with male patients being prescribed significantly higher doses of cannabis (25.48 ± 15.15 g) and higher THC content (14 ± 6.56%) compared to female patients (17.32 ± 9.93 g; THC: 11.39 ± 6.48%).
DISCUSSION: The study highlights variations in cannabis prescription patterns based on both medical conditions and demographic factors. Male patients received higher doses and THC-rich formulations, while patients with gastrointestinal conditions had the highest cannabis prescription overall. These findings suggest the need for individualised cannabis therapy based on patient characteristics and the specific condition being treated.
CONCLUSION: Medicinal cannabis usage patterns vary significantly across disease and demographic groups. Personalised cannabis treatment plans, informed by both clinical and demographic factors, are essential to optimising patient outcomes. Further research is needed to develop more precise guidelines for prescribing medicinal cannabis.
PMID:40652292 | DOI:10.1186/s42238-025-00307-6
